Evidence map›Paper›PMID 28629357›Full record

ArticleBMC complementary and alternative medicine2017

XuefuZhuyu decoction protected cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy.

Xiaowen Shi, Haiyan Zhu, Yuanyuan Zhang, Mingmei Zhou, Danli Tang, Huamin Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary and alternative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Liquiritin fromJournal of analytical methods in chemistry · 2021
    Article
  17. Efficacy and Safety ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Xiaowen ShiCenter for Chinese Medical Therapy and Systems Biology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Haiyan ZhuDepartment of Microbiological & Biochemical Pharmacy, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, People's Republic of China. haiyanzhu@fudan.edu.cn.
Yuanyuan ZhangDepartment of Pharmacology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, People's Republic of China.
Mingmei ZhouCenter for Chinese Medical Therapy and Systems Biology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Danli TangInstitute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, No.16, Nanxiao Road, Dongzhimen, Beijing, 100700, People's Republic of China.
Huamin ZhangInstitute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, No.16, Nanxiao Road, Dongzhimen, Beijing, 100700, People's Republic of China. zhanghm@mail.cintcm.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNShanghai University of Traditional Chinese Medicine · CNFudan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXuefuZhuyu decoction (XFZY) is a well-known traditional Chinese herbal medicine for the treatment of various cardiovascular diseases, such as unstable angina pectoris and myocardial ischemia-reperfusion injury. However, the mechanism by which XFZY contributes to the amelioration of cardiac injury remains unclear.

methodsH9C2 cells were cultured under the hypoxic condition for 10 h and reoxygenated for 2 h. In the presence of various concentrations of XFZY for 12 h, the cell viability was measured by MTT assay. The protective effect of XFZY in hypoxia/reoxygenation (H/R) cell model was confirmed by measuring the amount of LDH released into the extracellular fluid. Cell apoptosis was measured by western blotting. The autophagy level of H9C2 cells and the correlative pathway were determined by transmission electron microscopy, Cyto-ID® Autophagy Detection Kit, and western blotting.

resultsIn this study, we investigated the effects of XFZY on H/R induced cardiac injury. The results showed that treatment with XFZY significantly inhibited autophagy induced by H/R, with decreased formation of autophagosomes as well as the expression of LC3-II/LC3-I ratio and Beclin 1 after H/R. Importantly, inhibition of autophagy by XFZY resulted in enhanced cell viability and decreased apoptosis. XFZY also inhibited the activation of AMPK and upregulated the phosphorylation of mammalian target of Rapamycin (mTOR).

conclusionsThe cardioprotective effects of XFZY during H/R were mediated by inhibiting autophagy via regulating AMPK-mTOR signaling pathways.

Indexed as

AMP-Activated Protein KinasesAnimalsApoptosisAutophagyCell LineCell SurvivalDrugs, Chinese HerbalHumansHypoxiaMaleMyocardial Reperfusion InjuryMyocytes, CardiacPhosphorylationRatsRats, Sprague-DawleyTOR Serine-Threonine KinasesAMP-Activated Protein KinasesDrugs, Chinese HerbalmTOR protein, ratTOR Serine-Threonine KinasesAutophagyHypoxia/reoxygenationIschemic/reperfusionmTORXuefuZhuyu decoction

Identifiers

PMID28629357
PMCPMC5477241
OpenAlexW2665816257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.